Beranda › Kanker Paru › Pennsylvania › Reading
Uji klinis Kanker Paru di Reading, PA
11 studi untuk Kanker Paru mencari peserta di lokasi sekitar Reading (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Menerima pesertaFase 3
- Reading Hospital, West Reading · 1 mi jauhnya
- Ephrata Cancer Center, Ephrata · 17 mi jauhnya
- Sechler Family Cancer Center, Lebanon · 26 mi jauhnya
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Penn State Health Saint Joseph Medical Center, Reading
- Reading Hospital, West Reading · 1 mi jauhnya
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Menerima pesertaFase 3
- Reading Hospital, West Reading · 1 mi jauhnya
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Menerima pesertaFase 3
- Ephrata Cancer Center, Ephrata · 17 mi jauhnya
- Sechler Family Cancer Center, Lebanon · 26 mi jauhnya
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Menerima pesertaFase 3
- Reading Hospital, West Reading · 1 mi jauhnya
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Menerima pesertaFase 3
- Reading Hospital - McGlinn Cancer Institute, West Reading · 1 mi jauhnya
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Menerima pesertaFase 3
- Reading Hospital, West Reading · 1 mi jauhnya
- Ephrata Cancer Center, Ephrata · 17 mi jauhnya
- Sechler Family Cancer Center, Lebanon · 26 mi jauhnya
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- Ephrata Cancer Center, Ephrata · 17 mi jauhnya
- Sechler Family Cancer Center, Lebanon · 26 mi jauhnya
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- Ephrata Cancer Center, Ephrata · 17 mi jauhnya
- Sechler Family Cancer Center, Lebanon · 26 mi jauhnya
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2/3
- Ephrata Cancer Center, Ephrata · 17 mi jauhnya
- Sechler Family Cancer Center, Lebanon · 26 mi jauhnya
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
Menerima pesertaStudi observasional
- US Digestive Health at Wyomissing, Wyomissing · 2 mi jauhnya
Uji klinis Kanker Paru di kota lain
- Houston, TX78 studi
- Boston, MA62 studi
- New York City, NY60 studi
- Los Angeles, CA45 studi
- Washington, DC41 studi
- Arlington, VA41 studi
- Chicago, IL41 studi
- Nashville, TN40 studi
- Baltimore, MD40 studi
- St. Louis, MO39 studi
- Columbus, OH37 studi
- Philadelphia, PA36 studi
Studi lain di Reading
- Kanker Paru Non-Sel Kecil9 studi
- Leukemia Mieloid Akut5 studi
- Kanker Payudara5 studi
- Gangguan Somnolen Berlebih5 studi
- Kanker Prostat4 studi
- Kanker (semua jenis)4 studi
- Kanker Kolorektal3 studi
- Narkolepsi3 studi
- Gangguan Tidur3 studi
- Kelelahan3 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.